RNF213 and cholesteryl ester measurement: RNF213 p.Arg4810Lys was detected in 1.1% of the patients (1/93) with CE, 10.3% of the patients (10/97) with LAA, 0% of the patients (0/59) with SVO, 50% of the patients (2/4) with MMD, 0.8% of the patients (1/124) with other types excluding MMD, and 2.3% of the patients (3/131) with ICH.